Published in Nat Rev Microbiol on December 01, 2003
Electrical detection of single viruses. Proc Natl Acad Sci U S A (2004) 3.83
The papain-like protease of severe acute respiratory syndrome coronavirus has deubiquitinating activity. J Virol (2005) 2.49
The economy-wide impact of pandemic influenza on the UK: a computable general equilibrium modelling experiment. BMJ (2009) 2.35
Human coronavirus NL63 employs the severe acute respiratory syndrome coronavirus receptor for cellular entry. Proc Natl Acad Sci U S A (2005) 2.21
Metagenomic analysis of the viromes of three North American bat species: viral diversity among different bat species that share a common habitat. J Virol (2010) 2.18
Identification of severe acute respiratory syndrome coronavirus replicase products and characterization of papain-like protease activity. J Virol (2004) 1.97
Molecular evolution analysis and geographic investigation of severe acute respiratory syndrome coronavirus-like virus in palm civets at an animal market and on farms. J Virol (2005) 1.93
Evasion of antibody neutralization in emerging severe acute respiratory syndrome coronaviruses. Proc Natl Acad Sci U S A (2005) 1.75
Middle East respiratory syndrome coronavirus: another zoonotic betacoronavirus causing SARS-like disease. Clin Microbiol Rev (2015) 1.64
Evaluation of human monoclonal antibody 80R for immunoprophylaxis of severe acute respiratory syndrome by an animal study, epitope mapping, and analysis of spike variants. J Virol (2005) 1.54
Emerging respiratory viruses: challenges and vaccine strategies. Clin Microbiol Rev (2006) 1.52
Functional and genetic analysis of coronavirus replicase-transcriptase proteins. PLoS Pathog (2005) 1.52
Highly conserved regions within the spike proteins of human coronaviruses 229E and NL63 determine recognition of their respective cellular receptors. J Virol (2006) 1.49
Pathogen evolution and disease emergence in carnivores. Proc Biol Sci (2007) 1.43
Cleavage and activation of the severe acute respiratory syndrome coronavirus spike protein by human airway trypsin-like protease. J Virol (2011) 1.37
Systematic assembly of a full-length infectious clone of human coronavirus NL63. J Virol (2008) 1.23
Assembly of severe acute respiratory syndrome coronavirus RNA packaging signal into virus-like particles is nucleocapsid dependent. J Virol (2005) 1.21
Why SARS will not return: a polemic. CMAJ (2004) 1.15
Mutation in murine coronavirus replication protein nsp4 alters assembly of double membrane vesicles. Virology (2008) 1.13
Structural characterization of the fusion-active complex of severe acute respiratory syndrome (SARS) coronavirus. Proc Natl Acad Sci U S A (2004) 1.12
Putative cis-acting stem-loops in the 5' untranslated region of the severe acute respiratory syndrome coronavirus can substitute for their mouse hepatitis virus counterparts. J Virol (2006) 1.06
Murine hepatitis virus replicase protein nsp10 is a critical regulator of viral RNA synthesis. J Virol (2007) 1.06
Analysis of murine hepatitis virus strain A59 temperature-sensitive mutant TS-LA6 suggests that nsp10 plays a critical role in polyprotein processing. J Virol (2007) 1.04
SARS molecular epidemiology: a Chinese fairy tale of controlling an emerging zoonotic disease in the genomics era. Philos Trans R Soc Lond B Biol Sci (2007) 1.03
Suppression of host gene expression by nsp1 proteins of group 2 bat coronaviruses. J Virol (2009) 0.98
Gene 5 of the avian coronavirus infectious bronchitis virus is not essential for replication. J Virol (2005) 0.96
Gene expression profiles in peripheral blood mononuclear cells of SARS patients. World J Gastroenterol (2005) 0.95
Molecular mapping of the RNA Cap 2'-O-methyltransferase activation interface between severe acute respiratory syndrome coronavirus nsp10 and nsp16. J Biol Chem (2010) 0.93
Contribution of trafficking signals in the cytoplasmic tail of the infectious bronchitis virus spike protein to virus infection. J Virol (2005) 0.91
Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov (2016) 0.91
Small molecules with antiviral activity against the Ebola virus. F1000Res (2015) 0.90
A complex RNA motif defined by three discontinuous 5-nucleotide-long strands is essential for Flavivirus RNA replication. RNA (2008) 0.89
Coronavirus Nsp10, a critical co-factor for activation of multiple replicative enzymes. J Biol Chem (2014) 0.88
Specific epitopes of the structural and hypothetical proteins elicit variable humoral responses in SARS patients. J Clin Pathol (2006) 0.88
Functional transcriptional regulatory sequence (TRS) RNA binding and helix destabilizing determinants of murine hepatitis virus (MHV) nucleocapsid (N) protein. J Biol Chem (2012) 0.87
Studies on membrane topology, N-glycosylation and functionality of SARS-CoV membrane protein. Virol J (2009) 0.87
SARS-CoV proteins decrease levels and activity of human ENaC via activation of distinct PKC isoforms. Am J Physiol Lung Cell Mol Physiol (2008) 0.87
The structure and functions of coronavirus genomic 3' and 5' ends. Virus Res (2015) 0.87
Aptamer-based therapeutics: new approaches to combat human viral diseases. Pharmaceuticals (Basel) (2013) 0.86
SARS-coronavirus open reading frame-9b suppresses innate immunity by targeting mitochondria and the MAVS/TRAF3/TRAF6 signalosome. J Immunol (2014) 0.86
Coronavirus reverse genetic systems: infectious clones and replicons. Virus Res (2014) 0.84
One severe acute respiratory syndrome coronavirus protein complex integrates processive RNA polymerase and exonuclease activities. Proc Natl Acad Sci U S A (2014) 0.84
Human coronavirus NL63 utilizes heparan sulfate proteoglycans for attachment to target cells. J Virol (2014) 0.83
Emerging and re-emerging viruses in the era of globalisation. Blood Transfus (2009) 0.83
Cooperative translocation enhances the unwinding of duplex DNA by SARS coronavirus helicase nsP13. Nucleic Acids Res (2010) 0.82
Molecular advances in severe acute respiratory syndrome-associated coronavirus (SARS-CoV). Genomics Proteomics Bioinformatics (2003) 0.81
Induction of specific immune responses by severe acute respiratory syndrome coronavirus spike DNA vaccine with or without interleukin-2 immunization using different vaccination routes in mice. Clin Vaccine Immunol (2007) 0.81
Solution structure of mouse hepatitis virus (MHV) nsp3a and determinants of the interaction with MHV nucleocapsid (N) protein. J Virol (2013) 0.81
Molecular mechanisms of severe acute respiratory syndrome (SARS). Respir Res (2005) 0.81
Searching immunodominant epitopes prior to epidemic: HLA class II-restricted SARS-CoV spike protein epitopes in unexposed individuals. Int Immunol (2008) 0.79
Understanding Viral Transmission Behavior via Protein Intrinsic Disorder Prediction: Coronaviruses. J Pathog (2012) 0.79
Substitution at aspartic acid 1128 in the SARS coronavirus spike glycoprotein mediates escape from a S2 domain-targeting neutralizing monoclonal antibody. PLoS One (2014) 0.79
Traditional Chinese medicine herbal extracts of Cibotium barometz, Gentiana scabra, Dioscorea batatas, Cassia tora, and Taxillus chinensis inhibit SARS-CoV replication. J Tradit Complement Med (2011) 0.77
SARS-CoV genome polymorphism: a bioinformatics study. Genomics Proteomics Bioinformatics (2005) 0.77
SARS-CoV fusion peptides induce membrane surface ordering and curvature. Sci Rep (2016) 0.76
Engineering infectious cDNAs of coronavirus as bacterial artificial chromosomes. Methods Mol Biol (2015) 0.76
SHAPE analysis of the RNA secondary structure of the Mouse Hepatitis Virus 5' untranslated region and N-terminal nsp1 coding sequences. Virology (2014) 0.76
p53 down-regulates SARS coronavirus replication and is targeted by the SARS-unique domain and PLpro via E3 ubiquitin ligase RCHY1. Proc Natl Acad Sci U S A (2016) 0.76
SARS-coronavirus protein 6 conformations required to impede protein import into the nucleus. Virus Res (2010) 0.76
Neutralizing epitopes of the SARS-CoV S-protein cluster independent of repertoire, antigen structure or mAb technology. MAbs (2010) 0.76
Reassessing Biological Threats: Implications for Cooperative Mitigation Strategies. Front Public Health (2015) 0.75
HTCC: Broad Range Inhibitor of Coronavirus Entry. PLoS One (2016) 0.75
Expression, crystallization and preliminary crystallographic study of the C-terminal half of nsp2 from SARS coronavirus. Acta Crystallogr Sect F Struct Biol Cryst Commun (2011) 0.75
Detection of airborne viruses using electro-aerodynamic deposition and a field-effect transistor. Sci Rep (2015) 0.75
Crystal structure of Middle East respiratory syndrome coronavirus helicase. PLoS Pathog (2017) 0.75
Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med (2003) 27.97
Genome analysis of multiple pathogenic isolates of Streptococcus agalactiae: implications for the microbial "pan-genome". Proc Natl Acad Sci U S A (2005) 14.59
Human and avian influenza viruses target different cell types in cultures of human airway epithelium. Proc Natl Acad Sci U S A (2004) 7.18
Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat Med (2005) 6.77
The microbial pan-genome. Curr Opin Genet Dev (2005) 5.93
Complete genome sequence and comparative genomic analysis of an emerging human pathogen, serotype V Streptococcus agalactiae. Proc Natl Acad Sci U S A (2002) 5.28
Overexpression of the alpha-2,6-sialyltransferase in MDCK cells increases influenza virus sensitivity to neuraminidase inhibitors. J Virol (2003) 5.11
Functional balance between haemagglutinin and neuraminidase in influenza virus infections. Rev Med Virol (2002) 5.09
An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus. Nat Med (2004) 4.89
Microbiology in the post-genomic era. Nat Rev Microbiol (2008) 4.88
The Ebola virus VP35 protein inhibits activation of interferon regulatory factor 3. J Virol (2003) 4.73
A universal vaccine for serogroup B meningococcus. Proc Natl Acad Sci U S A (2006) 4.45
Pili in gram-positive pathogens. Nat Rev Microbiol (2006) 4.21
New low-viscosity overlay medium for viral plaque assays. Virol J (2006) 3.92
Genome analysis reveals pili in Group B Streptococcus. Science (2005) 3.85
Identification of a universal Group B streptococcus vaccine by multiple genome screen. Science (2005) 3.83
Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870. J Exp Med (2003) 3.83
Proposal for a revised taxonomy of the family Filoviridae: classification, names of taxa and viruses, and virus abbreviations. Arch Virol (2010) 3.77
Neuraminidase is important for the initiation of influenza virus infection in human airway epithelium. J Virol (2004) 3.43
Interaction of polymerase subunit PB2 and NP with importin alpha1 is a determinant of host range of influenza A virus. PLoS Pathog (2008) 3.37
NadA, a novel vaccine candidate of Neisseria meningitidis. J Exp Med (2002) 3.26
c-Src/Lyn kinases activate Helicobacter pylori CagA through tyrosine phosphorylation of the EPIYA motifs. Mol Microbiol (2002) 3.20
IL28B polymorphisms predict interferon-related hepatitis B surface antigen seroclearance in genotype D hepatitis B e antigen-negative patients with chronic hepatitis B. Hepatology (2012) 3.12
Coxsackie B4 virus infection of beta cells and natural killer cell insulitis in recent-onset type 1 diabetic patients. Proc Natl Acad Sci U S A (2007) 3.11
Receptor-binding specificity of pandemic influenza A (H1N1) 2009 virus determined by carbohydrate microarray. Nat Biotechnol (2009) 3.07
Properties of replication-competent vesicular stomatitis virus vectors expressing glycoproteins of filoviruses and arenaviruses. J Virol (2004) 2.99
Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment. Lancet Infect Dis (2013) 2.95
Proteolytic activation of influenza viruses by serine proteases TMPRSS2 and HAT from human airway epithelium. J Virol (2006) 2.80
MF59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza vaccines. Sci Transl Med (2011) 2.75
Ebola virus: from discovery to vaccine. Nat Rev Immunol (2003) 2.72
Inhibition of natural killer cells through engagement of CD81 by the major hepatitis C virus envelope protein. J Exp Med (2002) 2.64
Structure and dynamics of the pan-genome of Streptococcus pneumoniae and closely related species. Genome Biol (2010) 2.60
Nonviral delivery of self-amplifying RNA vaccines. Proc Natl Acad Sci U S A (2012) 2.59
Rational design of a meningococcal antigen inducing broad protective immunity. Sci Transl Med (2011) 2.59
Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels. Proc Natl Acad Sci U S A (2009) 2.41
Prospects for a vaccine against the hepatitis C virus. Nature (2005) 2.38
Altered receptor specificity and cell tropism of D222G hemagglutinin mutants isolated from fatal cases of pandemic A(H1N1) 2009 influenza virus. J Virol (2010) 2.38
A novel glyco-conjugate vaccine against fungal pathogens. J Exp Med (2005) 2.35
Nucleic acid-sensing Toll-like receptors are essential for the control of endogenous retrovirus viremia and ERV-induced tumors. Immunity (2012) 2.35
Hemagglutination inhibition antibody titers as a correlate of protection for inactivated influenza vaccines in children. Pediatr Infect Dis J (2011) 2.33
Crystal structure of the borna disease virus nucleoprotein. Structure (2003) 2.30
Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines. Proc Natl Acad Sci U S A (2010) 2.30
Hepatic expansion of a virus-specific regulatory CD8(+) T cell population in chronic hepatitis C virus infection. J Clin Invest (2004) 2.25
Reverse vaccinology: developing vaccines in the era of genomics. Immunity (2010) 2.25
Diagnostic reverse-transcription polymerase chain reaction kit for filoviruses based on the strain collections of all European biosafety level 4 laboratories. J Infect Dis (2007) 2.22
Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus. Sci Transl Med (2010) 2.21
Invariant NKT cells sustain specific B cell responses and memory. Proc Natl Acad Sci U S A (2007) 2.20
Identification of iron-activated and -repressed Fur-dependent genes by transcriptome analysis of Neisseria meningitidis group B. Proc Natl Acad Sci U S A (2003) 2.17
Group B Streptococcus: global incidence and vaccine development. Nat Rev Microbiol (2006) 2.16
Global suppression of the host antiviral response by Ebola- and Marburgviruses: increased antagonism of the type I interferon response is associated with enhanced virulence. J Virol (2006) 2.14
Distinct microRNA signatures in human lymphocyte subsets and enforcement of the naive state in CD4+ T cells by the microRNA miR-125b. Nat Immunol (2011) 2.11
Fur functions as an activator and as a repressor of putative virulence genes in Neisseria meningitidis. Mol Microbiol (2004) 2.08
Structural basis for immunization with postfusion respiratory syncytial virus fusion F glycoprotein (RSV F) to elicit high neutralizing antibody titers. Proc Natl Acad Sci U S A (2011) 2.08
Neisseria meningitidis NadA is a new invasin which promotes bacterial adhesion to and penetration into human epithelial cells. Mol Microbiol (2005) 2.06
Influenza vaccine immunology. Immunol Rev (2011) 2.02
Cryo-electron tomography of Marburg virus particles and their morphogenesis within infected cells. PLoS Biol (2011) 2.02
CD1d-restricted help to B cells by human invariant natural killer T lymphocytes. J Exp Med (2003) 2.01
New adjuvants for human vaccines. Curr Opin Immunol (2010) 1.98
DC-SIGN and DC-SIGNR interact with the glycoprotein of Marburg virus and the S protein of severe acute respiratory syndrome coronavirus. J Virol (2004) 1.92
Identification of Lassa virus glycoprotein signal peptide as a trans-acting maturation factor. EMBO Rep (2003) 1.85
Neisseria meningitidis is structured in clades associated with restriction modification systems that modulate homologous recombination. Proc Natl Acad Sci U S A (2011) 1.84
Previously unrecognized vaccine candidates against group B meningococcus identified by DNA microarrays. Nat Biotechnol (2002) 1.83
Transient facial nerve paralysis (Bell's palsy) following intranasal delivery of a genetically detoxified mutant of Escherichia coli heat labile toxin. PLoS One (2009) 1.82
Inhibition of filovirus replication by the zinc finger antiviral protein. J Virol (2006) 1.76
Activation of naïve B lymphocytes via CD81, a pathogenetic mechanism for hepatitis C virus-associated B lymphocyte disorders. Proc Natl Acad Sci U S A (2005) 1.76
The matrix protein VP40 from Ebola virus octamerizes into pore-like structures with specific RNA binding properties. Structure (2003) 1.75
Identification of protective and broadly conserved vaccine antigens from the genome of extraintestinal pathogenic Escherichia coli. Proc Natl Acad Sci U S A (2010) 1.75
Comparative genomics of Neisseria meningitidis: core genome, islands of horizontal transfer and pathogen-specific genes. Microbiology (2006) 1.75
Streptococcus pneumoniae pilus subunits protect mice against lethal challenge. Infect Immun (2006) 1.74
Vaccine manufacturing: challenges and solutions. Nat Biotechnol (2006) 1.73
Ectodomain shedding of the glycoprotein GP of Ebola virus. EMBO J (2004) 1.73
Antibody to genome-derived neisserial antigen 2132, a Neisseria meningitidis candidate vaccine, confers protection against bacteremia in the absence of complement-mediated bactericidal activity. J Infect Dis (2003) 1.73
A second pilus type in Streptococcus pneumoniae is prevalent in emerging serotypes and mediates adhesion to host cells. J Bacteriol (2008) 1.72
The new multicomponent vaccine against meningococcal serogroup B, 4CMenB: immunological, functional and structural characterization of the antigens. Vaccine (2012) 1.71
Ebola virus VP30-mediated transcription is regulated by RNA secondary structure formation. J Virol (2002) 1.71
The region comprising amino acids 100 to 255 of Neisseria meningitidis lipoprotein GNA 1870 elicits bactericidal antibodies. Infect Immun (2005) 1.68
Structure-based antigen design: a strategy for next generation vaccines. Trends Biotechnol (2008) 1.68
Neisseria meningitidis GNA2132, a heparin-binding protein that induces protective immunity in humans. Proc Natl Acad Sci U S A (2010) 1.66
Mucosal administration of Ag85B-ESAT-6 protects against infection with Mycobacterium tuberculosis and boosts prior bacillus Calmette-Guerin immunity. J Immunol (2006) 1.66
Differential use of importin-α isoforms governs cell tropism and host adaptation of influenza virus. Nat Commun (2011) 1.65
Clonal success of piliated penicillin nonsusceptible pneumococci. Proc Natl Acad Sci U S A (2007) 1.64